• Accolade for CAPRISA’s Research Pharmacist

    C APRISA’s Senior Research Pharmacist, Ms Anushka Naidoo, scooped the best presenta-tion award at the 19th International Confer-ence on Tuberculosis Therapy (ICTT 2017), hosted by the World Academy of Science, Engineering and Technology. Her presentation focussed on the effect of rifampicin and efavirenz on moxifloxacin concen-trations when co-administered in patients with drug susceptible tuberculosis (published in the Journal of Antimicrobial Chemotherapy 2017:doi:10.1093/jac/dkx004).

    The study was conducted within the Improving Retreatment Success Clinical (IMPRESS) trial, which compared the pharmacokinetics of moxifloxa-cin during co-treatment with rifampicin or when dosed alone in African patients with drug suscepti-ble, recurrent tuberculosis, the majority of whom were HIV co-infected and on efavirenz-based ART. "The conference was a really great opportunity to share our study findings with the TB research community," said Naidoo. She said receiving the best presentation award "was really exciting and an hon-our for myself and the study team."

    The ICTT is considered the premier interdisciplinary forum for the presentation of new advances and research results in the field of tuberculosis therapy.

    Share this article


Centre for the AIDS Programme of Research in South Africa

CAPRISA was created in 2001 and formally established in 2002 under the NIH-funded Comprehensive International Program of Research on AIDS (CIPRA) by five partner institutions; University of KwaZulu-Natal, University of Cape Town, University of Western Cape, National Institute for Communicable Diseases, and Columbia University in New York. CAPRISA is a designated UNAIDS Collaborating Centre for HIV Prevention Research. The main goal of CAPRISA is to undertake globally relevant and locally responsive research that contributes to understanding HIV pathogenesis, prevention and epidemiology as well as the links between tuberculosis and AIDS care.